NEW YORK (GenomeWeb News) – CombiMatrix said today that its chromosomal microarray test for miscarriage analysis has received conditional approval from the New York State's Department of Health, allowing the company to begin testing patient samples from the state.

"Gaining the conditional license and ultimately the final approval to market and sell our [Product of Conception] test throughout New York is an important milestone for us that will allow us to broaden the market for our number one growth product," CEO Mark McDonough said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.